RE:RE:APR was acquired for 7x adj. EBITDA, VMD at 4.5x adj. EBITDAAt the Stifel CC (Nov 16, 2021), the Moderator asked about the big picture post covid which we hope is not in the too distant future. If we are in a steady state how should we think about Viemed's top line and margin profile.
Casey Hoyt responded where he said we are never satisfied unless we grow north of 30%. We are used to growing at 30-40% range. We grew the core business at 20% in 2020 and we will be at the high teens in 2021 and while we had a lot of headwinds - access issues are probably the biggest thing that slowed us down. But we are very excited to get on the tail end of the pandemic....
We had a very good July and then the Delta variant slowed us down. September was a bit better than August and October was better than September but wasn't as busy as July but we know that once we turn this thing back on, hopefully....we want to pursue that 30-40% growth rate.
Of course Omicron surge would have impacted access to the hospitals from mid-December 2021 to mid-Feb 2022. So it will moderate some of the results in those quarters.